Compare PDX & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | BHVN |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.2M | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | PDX | BHVN |
|---|---|---|
| Price | $21.43 | $11.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $29.79 |
| AVG Volume (30 Days) | N/A | ★ 3.1M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,147.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.52 | $7.48 |
| 52 Week High | $21.05 | $44.28 |
| Indicator | PDX | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 53.32 |
| Support Level | $21.39 | $8.50 |
| Resistance Level | $22.15 | $11.80 |
| Average True Range (ATR) | 0.34 | 0.91 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 56.35 | 81.83 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.